Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Depression a potential risk factor for nonalcoholic fatty liver disease

01 Sep 2019

Depression is prevalent in nonalcoholic fatty liver disease (NAFLD), according to a recent study, suggesting that the psychiatric condition may be an independent risk factor for NAFLD.

The study included 10,484 individuals (mean age, 47.0 years; 48.8 percent male), among whom 1,162 had depression. Compared with those without the condition, individuals with depression were older (mean age 49.5 vs 47.0 years), more likely to be female (68.1 percent vs 49.2 percent), diabetic (17.6 percent vs 11.2 percent), hypertensive (41.0 percent vs 29.9 percent) and smoker (35.6 percent vs 16.8 percent). They also had a higher body mass index and waist circumference, and elevated levels of total cholesterol, triglyceride and fasting glucose.

The prevalence of depression and related functional impairment was higher in individuals with vs without NAFLD (p<0.001). Similarly, individuals with depression were more likely to have NAFLD compared with those who did not have the psychiatric condition.

Logistic regression analysis showed that depression as defined by antidepressant use was associated with increased risk of NAFLD as assessed using the following: Fatty Liver Index (FLI; odds ratio [OR] 2.01, 95 percent CI, 1.65–2.48), US FLI (OR, 1.48, 1.17–1.87) and HSI (OR, 1.51, 1.04–2.19). When diabetes, obesity and lipid profile were factored into the model, the risk estimates were attenuated but the significance persisted.

Depression was not associated with NAFLD‐related advanced fibrosis.

Despite the need for prospective data, the current findings indicate that appropriate screening and prompt treatment of depression may prevent the development or progression of NAFLD, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.